Disc Medicine posts smaller-than-expected Q2 net loss - IRON News | Rallies

Disc Medicine posts smaller-than-expected Q2 net loss

IRON•2026-07-30

What drove expenses

Pipeline advancement - Co said higher R&D expenses were driven by advancement of selcodebart and DISC-3405 clinical studies and drug manufacturing
Headcount increase - Co said higher SG&A and R&D expenses were partly due to increased headcount
Bitopertin manufacturing costs - Decrease in bitopertin manufacturing costs partially offset R&D expense increases

Q2 loss beat expectations

US biopharma firm's Q2 net loss and operating income both beat analyst expectations
Q2 loss per share was better than expected
Operating expenses rose yr/yr due to pipeline advancement and higher headcount


Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Net Loss	Beat	$59.53 mln	$68.24 mln (9 Analysts)
Q2 Loss Per Basic Share	Beat	$1.54	$1.75 (10 Analysts)
Q2 Operating Income	Beat	-$65.08 mln	-$71.04 mln (10 Analysts)
Q2 Operating Expenses		$65.08 mln

Analyst coverage and valuation

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Related News

Scottish government awards Planet Labs 7-figure contract for AI-enabled agricultural monitoring

PL•2026-07-30

Street View: Not out of the wash yet but signs are emerging for P&G

PG•2026-07-30

Builders FirstSource falls after lowering annual sales outlook